Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics’ EPS missed expectations in the second fiscal quarter of 2026, with results reported August 10, 2026 based on preliminary figures: EPS of -$1.14 trailed the -$1.07 estimate by -$0.07, and net income was a loss of roughly $85.9 million (down 29.9% year over year from a loss of -$66.1 million). The company, which is advancing antibody programs including APG777 and APG808, also posted an operating loss of about $96.0 million, while operating cash flow was negative at roughly $71.4 million. On a year-over-year basis, EPS of -$1.14 compared with -$1.13 a year ago (down 0.9%). For the next period, consensus calls for EPS of -$1.14 on revenue of $10.0 million.